[{"id":"62adebca-4b95-438d-afa0-1e8661c4fb8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05262530","created_at":"2022-03-02T16:52:30.929Z","updated_at":"2025-02-25T16:26:48.535Z","phase":"Phase 1/2","brief_title":"Safety and Preliminary Efficacy Trial of BNT142 in Patients with CLDN6-positive Solid Tumors","source_id_and_acronym":"NCT05262530","lead_sponsor":"BioNTech SE","biomarkers":" CLDN6","pipe":" | ","alterations":" CLDN6 positive","tags":["CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT142"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 03/28/2022","start_date":" 03/28/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-01-31"},{"id":"4898b5ad-3c9a-468d-8fed-e1f7bd83f3ff","acronym":"CARVac","url":"https://clinicaltrials.gov/study/NCT04503278","created_at":"2021-05-18T06:52:33.666Z","updated_at":"2025-02-25T16:25:57.832Z","phase":"Phase 1","brief_title":"A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors","source_id_and_acronym":"NCT04503278 - CARVac","lead_sponsor":"BioNTech Cell \u0026 Gene Therapies GmbH","biomarkers":" AFP • CLDN6","pipe":" | ","alterations":" CLDN6 expression • CLDN6 positive","tags":["AFP • CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 expression • CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT211"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2040","study_completion_date":" 01/01/2040","last_update_posted":"2024-05-31"},{"id":"9a153527-03e4-4f0e-a267-102de598735a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05410717","created_at":"2022-06-08T11:58:15.716Z","updated_at":"2024-07-02T16:35:24.094Z","phase":"Phase 1","brief_title":"CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors","source_id_and_acronym":"NCT05410717","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" AXL • MSLN • CLDN6 • GPC3","pipe":" | ","alterations":" CLDN6 expression • CLDN6 positive","tags":["AXL • MSLN • CLDN6 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 expression • CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6-CAR-NK cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 05/31/2034","study_completion_date":" 05/31/2034","last_update_posted":"2024-01-09"},{"id":"cbd3eb95-a6b5-4374-a565-cf5286d2e1ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05735366","created_at":"2023-02-21T16:01:47.196Z","updated_at":"2024-07-02T16:35:29.755Z","phase":"Phase 1","brief_title":"A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05735366","lead_sponsor":"Chugai Pharmaceutical","biomarkers":" CLDN6","pipe":" | ","alterations":" CLDN6 positive","tags":["CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • SAIL66"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-11-09"}]